Overview Breast cancer remains the most commonly diagnosed cancer worldwide, with the estrogen receptor–positive, HER2-negative (HR+/HER2−) subtype accounting for a large portion of cases. When breast cancer recurs, patients may face an elevated risk of thromboembolic events (TEEs), including deep vein thrombosis and pulmonary embolism. Understanding and assessing this thrombotic risk is crucial for guiding…